This review highlights the complex relationship between atrial fibrillation and ischemic heart disease, emphasizing the need for tailored antithrombotic therapy to balance ischemic and bleeding risks.
Answers are grounded in this paper and cite their sources.
Requires careful ischemic-bleeding risk balancing in AF with CAD; leaves open optimal regimens for prospective trials.
The article discusses the issue of searching for optimum oral anticoagulants to prevent thrombosis and embolism induced by heart disease both in patients with atrial fibrillation and sinus rhythm. A complex bidirectional relationship between atrial fibrillation and coronary atherosclerosis is considered along with possible mechanisms for development of myocardial infarction in patients with atrial fibrillation. The authors provided evidence-based data which can be used in selecting an anticoagulant for prevention of heart disease induced thrombosis and embolism taking into account both the efficacy and safety established in randomized clinical studies.
No takes yet. Share an insight, caveat, or question.
Gilyarevskiy et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: